Scholarlink

Purpose <p>To investigate regional differences in the epidemiology and treatment of retinopathy of prematurity (ROP) from 2016 to 2023.</p> Study design <p>Retrospective multicenter cohort study</p> Methods <p>Premature infants screened for ROP at a single tertiary referral center in each of five countries/regions (Taiwan, Hong Kong, Singapore, India, and Portugal) during the study period. Demographic characteristics, incidences of ROP and type 1 ROP, and treatment modalities were analyzed. Screening criteria followed local protocols. Logistic regression was used to assess trends, and intergroup comparisons were performed using Kruskal–Wallis and chi-square tests.</p> Results <p>A total of 15,031 premature infants were enrolled. Demographics varied significantly (<i>p</i> &lt;0.001); India had the highest gestational age and birth weight, and the lowest proportion of very low birth weight and extremely low birth weight infants with type 1 ROP (<i>p</i> &lt;0.001). Hong Kong had the lowest ROP incidence, while Singapore showed a significant increase over time (<i>p</i> = 0.003). Type 1 ROP rates were higher in Taiwan and India than in Hong Kong and Singapore, with a significant decline observed only in Taiwan (<i>p =</i> 0.005). Anti-Vascular Endothelial Growth Factor (Anti-VEGF) injections were increasingly preferred as initial treatment, with bevacizumab being the most frequently used (87.3%).</p> Conclusion <p>From 2016 to 2023, ROP incidence and treatment showed significant regional differences. ROP increased in Singapore, while type 1 ROP decreased significantly in Taiwan. Although anti-VEGF therapy has become more common, laser treatment remains dominant in Hong Kong.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epidemiology and treatment trends of retinopathy of prematurity: a multi-center study involving four Asian centers and one European center (2016–2023)

  • 期刊论文

  • 发表日期：

    2026年7月3日

查看全文
  • Yi-Hsuan Tseng,
  • Tapas Ranjan Padhi,
  • Souvik Bhunia,
  • Sudarshan Seshasai,
  • Andrew Shih-Hsiang Tsai,
  • Gavin Siew-Wei Tan,
  • Nirmal Kavalloor Visruthan,
  • Connie Hong Yee Lai,
  • Tin Yan Grace Hui,
  • Rachel Sze-wan Yiu,
  • Susana Maria Pereira Teixeira,
  • Tomas Reis da Costa,
  • Pei-Liang Wu,
  • Eugene Yu-Chuan Kang,
  • Kuan-Jen Chen,
  • Nan-Kai Wang,
  • Yih-Shiou Hwang,
  • Chi-Chun Lai,
  • Wei-Chi Wu

摘要

Purpose

To investigate regional differences in the epidemiology and treatment of retinopathy of prematurity (ROP) from 2016 to 2023.

Study design

Retrospective multicenter cohort study

Methods

Premature infants screened for ROP at a single tertiary referral center in each of five countries/regions (Taiwan, Hong Kong, Singapore, India, and Portugal) during the study period. Demographic characteristics, incidences of ROP and type 1 ROP, and treatment modalities were analyzed. Screening criteria followed local protocols. Logistic regression was used to assess trends, and intergroup comparisons were performed using Kruskal–Wallis and chi-square tests.

Results

A total of 15,031 premature infants were enrolled. Demographics varied significantly (p <0.001); India had the highest gestational age and birth weight, and the lowest proportion of very low birth weight and extremely low birth weight infants with type 1 ROP (p <0.001). Hong Kong had the lowest ROP incidence, while Singapore showed a significant increase over time (p = 0.003). Type 1 ROP rates were higher in Taiwan and India than in Hong Kong and Singapore, with a significant decline observed only in Taiwan (p = 0.005). Anti-Vascular Endothelial Growth Factor (Anti-VEGF) injections were increasingly preferred as initial treatment, with bevacizumab being the most frequently used (87.3%).

Conclusion

From 2016 to 2023, ROP incidence and treatment showed significant regional differences. ROP increased in Singapore, while type 1 ROP decreased significantly in Taiwan. Although anti-VEGF therapy has become more common, laser treatment remains dominant in Hong Kong.